위암의 근치적 절제술 후 고위험군에 대한 보조적 FP(5-FU, Cisplatin) 복합화학요법
Postoperative FP(5-Fluorouracil, Cisplatin) Chemotherapy for Patients with Righ-Risk Gastric Cancer
대한암학회지 1998년 30권 3호 p.482 ~ 487
소속 상세정보
이기형/Ki Hyeong Lee
고병성/신형식/박선미/윤세진/김승택/Byeong Seong Ko/Hyoung Shik Shin/Seon Mee Park/Sei Jin Youn/Seung Taik Kim
KMID : 0360319980300030482
Abstract
결론
위암의 수술 후 고 위험군인 stage Ⅲ, Ⅳ 환자들을 대상으로 진행 위암에 가장 효과적인
치료법 중의 하나인 FP 복합화학요법을 보조화학요법으로 시도한 결과 독성은 수용 가능한
정도였으며 2년 생존율 및 무병 생존율은 각각 63% 및 49%로 기존의 다른 치료방법에 비
하여 크게 다르지 않았다. 향후 보다 장기간의 추적 관찰을 통하여 제 3상 임상연구 여부를
결정해야 할 것으로 사료된다.
#초록#
Purpose : Although adjuvant chemotherapy after resection of gastric cancer is a
popular practice in Korea, there are still controversies about the effectiveness of the
treatment. The fact that the relatively less effective drugs have been used and the rarity
of large-scaled controlled studies may be partially responsible for the controversies.
FP(5-FU, Cisplatin) combination is one of the most active regimen against advanced
gastric cancer, consistently showing a response rate of 50∼60%. We tried the FP
chemotherapy as an adjuvant treatment for high-risk patients after curative resection of
gastric cancer.
Materials and Methods : Between February 1992 and June 1996, 35 patients with
completely resected high-risk gastric cancer(postoperative stage Ⅲ or Ⅳ except those
with M1) received six courses of FP chemotherapy. Endpoints were toxicities of
treatment, relapse free survival, and overall survival.
Results : With a median follow-up time of 17.1 months, Kaplan-Meier estimates of
2-year overall survival was 63.3% and relapse free survival estimates was 49%. There
were no differences between stage Ⅲ and Ⅳ patients in terms of overall survival or
relapse free survival. Hematologic and talon-hematologic toxicities were tolerable for
most of the patients.
Conclusion : Postoperative FP combination chemotherapy was tolerable for patients
with high-risk(stage Ⅲ and Ⅳ) gastric cancer. It is too early to determine the long
term survival rates for this patients, but 2-year overall and relapse free survival were
comparable to that of historical non-cisplatin containing regimens. Randomized phase Ⅲ
studies are warranted.
키워드
5-FU; Cisplatin; Adjuvant; Gastric cancer;
원문 및 링크아웃 정보
등재저널 정보